J&J defends Darzalex with FDA approval for faster dosing

J&J defends Darzalex with FDA approval for faster dosing

Source: 
Pharmaforum
snippet: 

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend off a challenge from Sanofi.